Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug
Doeser A, Dickhof G, Reitze M, Uebachs M, Schaub C, Pires NM, Bonifácio MJ, Soares-da-Silva P, Beck H
Contributed by Sloka Iyengar
Brain (2015) 138 (2): 371-387 First published online: 3 December 2014 DOI: http://dx.doi.org/10.1093/brain/awu339
The authors of a recent study examined whether eslicarbazepine acetate (ESL) could target refractoriness to AEDs in addition to halting epileptogenesis. Using tissue resected from individuals with refractory epilepsy and pilocarpine- treated rodents, they found that ESL conferred use-dependent blockade of Na+ channels, hence alluding to its potential role in decreasing refractoriness. ESL was also found to block CaV3.2 calcium channels, mossy fiber sprouting and decrease neurodegeneration, hence having a likely beneficial role in slowing epileptogenesis.
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community